New Delhi: Indian Drugs Controller General (DCGI) Dr. VG Somani on Tuesday allowed the Serum Institute of India (SII) to resume the Clinical Trail on the Corona vaccine candidates from Oxford.
DCGI rescinded its earlier order prohibiting the selection of any candidate for second and third stage testing. However DCGI has kept many other conditions including extra attention during the investigation.
DCGI has been asked by SII to submit information about treatment as per the rules in dealing with adverse situations. Earlier on September 11, DCGI directed the Serum Institute of India to stop the clinical trial of a possible vaccine for Kovid-19 as the pharmaceutical giant AstraZeneca reported ‘ill-health’ of one person involved in the study. In countries, testing was stopped.
